Disco is a clinical-stage biopharmaceutical company developing novel treatments for serious hematologic diseases by targeting fundamental pathways in red blood cell formation and function. The company's pipeline comprises therapies addressing heme biosynthesis and iron homeostasis, targeting rare disorders including erythropoietic porphyrias, myelofibrosis, inflammatory bowel disease, polycythemia vera, and sickle cell disease. As a clinical-stage company not yet generating product revenue, Disco's current financial model relies on upfront and milestone payments from in-licensing agreements with partners such as Roche and AbbVie, along with tiered royalty rates on net sales once products are commercialized and potential sublicense revenues from regional arrangements.